Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Francesca BovisTomas KalincikFred LublinGary CutterCharles MalpasDana HorakovaEva Kubala HavrdovaMaria TrojanoAlexandre PratMarc GirardPierre DuquetteMarco OnofrjAlessandra LugaresiGuillermo IzquierdoSara EichauFrancesco PattiMurat TerziPierre GrammondRoberto BergamaschiPatrizia SolaDiana FerraroSerkan OzakbasGerardo IulianoCavit BozRaymond HuppertsFrancois Grand'MaisonCelia Oreja-GuevaraVincent van PeschElisabetta CartechiniThor PetersenAyse AltintasAysun SoysalCristina Ramo-TelloPamela McCombeRecai TurkogluHelmut ButzkuevenJerry S WolinskyClaudio Marcello SolaroMaria Pia SormaniPublished in: Neurology (2020)
We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.